
Myriad Genetics, Inc.
- Jurisdiction
United States - LEI
52990044IHUOUMETT163 - ISIN
US62855J1043 (MYGN )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
3
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
4
/ 7
Profile
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. Read full profile
Fundamentals
- Net revenue
€710.42M - Gross margin
70.4% - EBIT
-€355.85M - EBIT margin
-50.1% - Net income
-€337.09M - Net margin
-47.4%
Statement period: - (published )
Estimates
Fiscal Year | Net revenue | Net income |
---|---|---|
|
| |
|
| |
|
|
Stock price
Dividends
- Last dividend amount
-
$1.75 - Ex date
-
Analyst ratings
No analyst ratings available
Insider Transactions
No insider transactions in the last 90 days. View older insider transactions
Earnings Calls
Investor transactions
Name | Shares | Value | Last change | Change type |
---|---|---|---|---|
Peter Brown |
|
|
|
Sell |
Earnings Calls
Latest earnings call: May 7, 2024 (Q1 2024)